Biotech stocks are often challenging for investors to evaluate without having a full scientific context, and Sarepta Therapeutics (NASDAQ: SRPT) is no exception. With multiple successful products on the market but no profits to speak of, it's a bit of an oddity -- but keen investors recognize that weirdness is often the first sign of an untapped opportunity.

So, with that idea in mind, let's examine three other tidbits that smart investors know about this company.

Sarepta aims to develop advanced therapies for rare diseases, especially for Duchenne muscular dystrophy (DMD), which is its focus. DMD only affects 1 out of 3,500 male newborns worldwide, and it's a hereditary degenerative disease that quickly takes a serious toll on patients.

Continue reading

Source Fool.com